Oral administration of BBR for 5 wk led to a trend but a nonsignificant reduction in the proinflammatory cytokine IL-6 levels in the breast tumor tissue of the BBR-treated group compared with the control group (P > 0.05) (Figure 5A). The gene discussed is IL6; the disease is breast neoplasm.